P-170 Glycoprotein (MDR) and p53 Expression in Breast Cancer.
An immunohistochemical comparative analysis of P-170 glycoprotein and p53 was performed in 37 breast cancer patients who underwent curative resection without preoperative chemotherapy. The antibodies utilized were C-219 and JSB-1 for P-gp and DO-7 for p53. Positive cytoplasmic and membrance positivity for P-gp was found in 22 (59.45%) of the 37 tumor specimens. In comparing tissue immunoreactivity by the specific antibodies, 15 (40.54%) samples showed immunostaining for C-219, 12 (32.43%) for JSB-1, and 5 (23%) for both. P-gp expression was not statistically related with the clinicopathological variables analyzed, that is, age, TNM stage, histologic type, lymph node involvement, tumor diameter, and hormone receptor status. p53 overexpression was observed in 22 (59.45%) of the 37 tumor samples analyzed. There was a significant correlation between p53 overexpression and P-gp positive immunostaining (p = .007). p53 was also significantly correlated with TNM stage (p < .05) and lymph node involvement (p < .02). Our results demonstrated that the three distinct patterns of reactivity with the two antibodies result from the combined expression of each of the three P-gp isoforms. An immunohistochemical analysis with different antibodies may be used to determine and correlate the expression pattern of P-gp isoforms with response to chemotherapy.